Literature DB >> 20629080

Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy.

Jian Z Wang1, Nina A Mayr, Dongqing Zhang, Kaile Li, John C Grecula, Joseph F Montebello, Simon S Lo, William T C Yuh.   

Abstract

BACKGROUND: The objectives of this study were to investigate outcome prediction by measuring absolute tumor volume and regression ratios using serial magnetic resonance imaging (MRI) during radiation therapy (RT) for cervical cancer and to develop algorithms capable of identifying patients at risk of a poor therapeutic outcome.
METHODS: Eighty patients with stage IB2 through IVA cervical cancer underwent 4 MRI scans: before RT (MRI1), during RT at 2 to 2.5 weeks (MRI2) at 4 to 5 weeks (MRI3), and 1 to 2 months after RT (MRI4). The median follow-up was 6.2 years (range, 0.2-9.4 years). Tumor volumes at MRI1, MRI2, MRI3, and MRI4 (V1, V2, V3, and V4, respectively) and tumor regression ratios (V2/V1, V3/V1, and V4/V1) were measured by 3-dimensional volumetry. Predictive metrics based on tumor volume/regression parameters were correlated with ultimate clinical outcomes, including tumor local recurrence (LR) and dying of disease (DOD). Predictive power was evaluated using the Mann-Whitney test, sensitivity/specificity analyses, and Kaplan-Meier analyses.
RESULTS: Both tumor volume and regression ratio were strongly correlated with LR (P=.06, P = 5×10(-4), P=1×10(-6), and P=2×10(-8) for V1, V2, V3, and V4, respectively; and P=7×10(-5), P=1×10(-6), and P=1×10(-8) for V2/V1, V3/V1, and V4/V1, respectively) and DOD (P=.015, P=.004, P=.001, and P=3×10(-4) for V1, V2, V3, and V4, respectively; and P=.03, P=.009, and P=3×10(-4) for V2/V1, V3/V1, and V4/V1, respectively). Algorithms that combined tumor volumes and regression ratios improved predictive power (sensitivity, 61%-89%; specificity, 79%-100%). The strongest predictor, pre-RT volume and regression ratio at MRI3 (V1>40 cm3 and V3/V1>20%, respectively), achieved 89% sensitivity, 87% specificity, and 88% accuracy for LR and achieved 54% sensitivity, 83% specificity, and 73% accuracy for DOD.
CONCLUSIONS: The current results suggested that tumor volume/regression parameters obtained during primary therapy are useful in predicting LR and DOD. Both tumor volume and regression ratio provided important information as early outcome predictors that may guide early intervention for patients with cervical cancer who are at high risk of treatment failure.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20629080      PMCID: PMC2958238          DOI: 10.1002/cncr.25260

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Problems with the Clinical Staging of Carcinoma of the Cervix.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1994-01       Impact factor: 5.934

2.  Invasive cervical carcinoma: comparison of MR imaging and surgical findings.

Authors:  H Hricak; C G Lacey; L G Sandles; Y C Chang; M L Winkler; J L Stern
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

3.  The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.

Authors:  E Kastritis; A Bamias; E Efstathiou; D Gika; G Bozas; P Zorzou; K Sarris; C Papadimitriou; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2005-07-26       Impact factor: 5.482

4.  Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging.

Authors:  K Hatano; Y Sekiya; H Araki; M Sakai; T Togawa; Y Narita; Y Akiyama; S Kimura; H Ito
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

5.  Magnetic resonance imaging in cervical cancer: a basis for objective classification.

Authors:  E Burghardt; H M Hofmann; F Ebner; J Haas; K Tamussino; E Justich
Journal:  Gynecol Oncol       Date:  1989-04       Impact factor: 5.482

6.  Stage IB or IIA-B carcinoma of the intact uterine cervix treated with irradiation: a multivariate analysis.

Authors:  G C Lowrey; W M Mendenhall; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

8.  The effect of volume of disease in patients with carcinoma of the uterine cervix.

Authors:  J J Kovalic; C A Perez; P W Grigsby; M A Lockett
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-09       Impact factor: 7.038

9.  Predicting outcomes in cervical cancer: a kinetic model of tumor regression during radiation therapy.

Authors:  Zhibin Huang; Nina A Mayr; William T C Yuh; Simon S Lo; Joseph F Montebello; John C Grecula; Lanchun Lu; Kaile Li; Hualin Zhang; Nilendu Gupta; Jian Z Wang
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  Invasive cervical carcinoma: role of MR imaging in pretreatment work-up--cost minimization and diagnostic efficacy analysis.

Authors:  H Hricak; C B Powell; K K Yu; E Washington; L L Subak; J L Stern; M G Cisternas; R L Arenson
Journal:  Radiology       Date:  1996-02       Impact factor: 11.105

View more
  27 in total

1.  Onset time of tumor repopulation for cervical cancer: first evidence from clinical data.

Authors:  Zhibin Huang; Nina A Mayr; Mingcheng Gao; Simon S Lo; Jian Z Wang; Guang Jia; William T C Yuh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-02       Impact factor: 7.038

2.  Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report.

Authors:  Matthew M Harkenrider; Merry Jennifer Markham; Don S Dizon; Anuja Jhingran; Ritu Salani; Ramy K Serour; Jean Lynn; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

3.  MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Authors:  T Seierstad; K H Hole; K K Grøholt; S Dueland; A H Ree; K Flatmark; K R Redalen
Journal:  Br J Radiol       Date:  2015-04-22       Impact factor: 3.039

4.  Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study.

Authors:  Jian Xiao; Yuting Tan; Wenyun Li; Jiaying Gong; Zhiyang Zhou; Yan Huang; Jian Zheng; Yanhong Deng; Lei Wang; Junsheng Peng; Donglin Ren; Ping Lan; Jianping Wang
Journal:  Oncol Lett       Date:  2015-04-07       Impact factor: 2.967

5.  Texture analysis versus conventional MRI prognostic factors in predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced cancer of the uterine cervix.

Authors:  Maria Ciolina; Valeria Vinci; Laura Villani; Silvia Gigli; Matteo Saldari; Pierluigi Benedetti Panici; Giorgia Perniola; Andrea Laghi; Carlo Catalano; Lucia Manganaro
Journal:  Radiol Med       Date:  2019-06-28       Impact factor: 3.469

6.  Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?

Authors:  Marie Voglimacci; Erwan Gabiache; Amélie Lusque; Gwenaël Ferron; Anne Ducassou; Denis Querleu; Stéphanie Motton; Elodie Chantalat; Frédéric Courbon; Alejandra Martinez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-07       Impact factor: 9.236

Review 7.  Magnetic resonance image guided brachytherapy.

Authors:  Kari Tanderup; Akila N Viswanathan; Christian Kirisits; Steven J Frank
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

8.  Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients. A low-field MRI study.

Authors:  M P Schmid; B Mansmann; M Federico; J C A Dimopoulous; P Georg; E Fidarova; W Dörr; R Pötter
Journal:  Strahlenther Onkol       Date:  2013-01-25       Impact factor: 3.621

9.  Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Stephanie Cardarella; David M Jackman; Michael S Rabin; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

Review 10.  Functional imaging to predict tumor response in locally advanced cervical cancer.

Authors:  Tara D Barwick; Alexandra Taylor; Andrea Rockall
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.